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Abstract CCN-2 (connective tissue growth factor; CTGF) is
a key factor in fibrosis. Plasma CCN-2 has biomarker poten-
tial in numerous fibrotic disorders, but it is unknown which
pathophysiological factors determine plasma CCN-2 levels.
The proteolytic amino-terminal fragment of CCN-2 is primar-
ily eliminated by the kidney. Here, we investigated elimina-
tion and distribution profiles of full length CCN-2 by intrave-
nous administration of recombinant CCN-2 to rodents. After
bolus injection in mice, we observed a large initial distribution
volume (454 mL/kg) and a fast initial clearance (120 mL/kg/
min). Immunosorbent assay and immunostaining showed that
CCN-2 distributed mainly to the liver and was taken up by
hepatocytes. Steady state clearance in rats, determined by con-
tinuous infusion of CCN-2, was fast (45 mL/kg/min). Renal
CCN-2 clearance, determined by arterial and renal vein sam-
pling, accounted for only 12 % of total clearance. Co-infusion
of CCN-2 with receptor-associated protein (RAP), an antago-
nist of LDL-receptor family proteins, showed that RAP
prolonged CCN-2 half-life and completely prevented CCN-2
internalization by hepatocytes. This suggests that hepatic up-
take of CCN-2 is mediated by a RAP-sensitive mechanism
most likely involving LRP1, a member of the LDL-receptor
family involved in hepatic clearance of various plasma pro-
teins. Surface plasmon resonance binding studies confirmed
that CCN-2 is an LRP1 ligand. Co-infusion of CCN-2 with an
excess of the heparan sulphate-binding protamine lowered the
large initial distribution volume of CCN-2 by 88 % and re-
duced interstitial staining of CCN-2, suggesting binding of
CCN-2 to heparan sulphate proteoglycans (HSPGs).
Protamine did not affect clearance rate, indicating that
RAP-sensitive clearance of CCN-2 is HSPG independent. In
conclusion, unlike its amino-terminal fragment which is
cleared by the kidney, full length CCN-2 is primarily elimi-
nated by the liver via a fast RAP-sensitive, probably LRP1-
dependent pathway.
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CCN CTGF/CYR61/NOV
CKD chronic kidney disease
CTGF connective tissue growth factor
CYR61 cysteine-rich 61
E. coli Escherichia coli
ELISA enzyme-linked immunosorbent assay
ERPF effective renal plasma flow
GFR glomerular filtration rate
GST-RAP glutathione S-transferase-fused
receptor-associated protein
HSPG heparan sulphate proteoglycan
LDL low density lipoprotein
LRP low density lipoprotein receptor-related protein
NOV nephroblastoma overexpressed
PAH para-aminohippuric acid
RAP receptor-associated protein
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Introduction
CTGF/CYR61/NOV −2 (CCN-2, also known as connective
tissue growth factor or CTGF) is a key factor in the pathogen-
esis of organ fibrosis. Circulating CCN-2 correlates with
fibrogenic activity in various chronic disorders and might be
useful as a non-invasive marker for monitoring fibrosis, in-
cluding liver fibrosis (Dendooven et al. 2011; Gressner et al.
2013; Guo-Qiu et al. 2010; Bauer et al. 2012; Honsawek et al.
2013; Colak et al. 2012). The CCN-2molecule is a 349–amino
acid polypeptide of 36–38 kDa which consists of four distinct
cysteine-rich interaction domains. Between domain 2 and 3 the
protein contains a cysteine-free hinge region, which is suscep-
tible to proteolytic cleavage generating N- and C-terminal frag-
ments of similar molecular weight. The N-fragment is the pre-
dominant CCN-2 molecule in plasma in healthy subjects and
chronic kidney disease patients, while full length CCN-2 is
hardly detectable by available techniques (Dendooven et al.
2011). In chronic liver disease, however, elevated circulating
levels of the full length protein were reported (Gressner et al.
2006; Guo-Qiu et al. 2010). Only sparse data are available on
circulating C-fragment levels and reported levels were lower
than those of the N-fragment and the full length molecule
(Weitz and Usinger 2003; Dziadzio et al. 2005).
Circulating CCN-2 levels are determined by tissue produc-
tion, release into the circulation, proteolytic cleavage, cell- and
matrix interaction and elimination processes. CCN-2 tissue
expression is generally increased in chronic fibrotic disorders
(Dendooven et al. 2011). However, plasma CCN-2 profiles
differ between various disorders perhaps because of different
pharmacokinetic profiles of the CCN-2 full-length protein and
its fragments and interferencewith different elimination routes
depending on which organ is affected. Previously, we demon-
strated that the N-fragment of CCN-2 is primarily eliminated
by the kidney resulting in accumulation of circulating N-
fragment in chronic kidney disease (CKD) (Gerritsen et al.
2012). The high levels of full length CCN-2 in chronic liver
disease and negligible levels in CKD suggest involvement of
the liver in clearance of the whole protein. Gao et al. reported
in vitro binding of CCN-2 via domain 3 to low density lipo-
protein receptor-related protein 1 (LRP1) (Gao and Brigstock
2003), a multifunctional endocytic receptor highly expressed
in liver and known to be involved in cellular uptake and sub-
sequent degradation of various proteins (Lillis et al. 2008).
Liver cirrhosis is associated with decreased expression of
LRP1 (Hollestelle et al. 2004). Low levels of full length
CCN-2 in healthy subjects might also be explained by binding
to cell surface or matrix. Previous reports show in vitro
binding of CCN-2 to heparan sulphate proteoglycans
(HSPGs) (Gao and Brigstock 2004). Since HSPGs are widely
distributed, full length CCN-2 released into the circulation
might be rapidly captured by HSPGs and removed from
plasma.
To investigate elimination and distribution profile of full
length CCN-2, we administered recombinant human full
length CCN-2 intravenously to rodents. In addition, we exam-
ined the involvement of LRP1 and HSPGs in clearance and
distribution of full length CCN-2 by co-infusion of competing
ligands.
Materials and methods
Proteins
Recombinant CCN-2 s and anti- CCN-2 antibodies were sup-
plied by FibroGen Inc. (San Francisco, CA). The recombinant
human CCN-2 s were produced in a baculovirus expression
system in Chinese Hamster Ovary cell lines cultured in hollow-
fiber fermentors. The proteins were purified by CCN-2-affinity
and cation exchange chromatography. Recombinant full length
CCN-2 comprised all four domains, the N-terminal fragment
comprised domain 1 and 2 and C-terminal fragment comprised
domain 3 and 4. Purified placenta-derived LRP1 was a kind
gift by Dr. S. K. Moestrup (University of Aarhus, Aarhus,
Denmark) (Moestrup and Gliemann 1991). The bacterial vec-
tor encoding glutathioneS-transferase-fused receptor-
associated protein was kindly provided by Dr. J. Kuiper
(Leiden University, Leiden, The Netherlands). Glutathione
S-transferase-fused receptor-associated protein (GST-RAP)
was expressed in E. coli strain DH5α and purified by
glutathione-Sepharose (Herz et al. 1991).
Animal experiments
Pharmacokinetic studies were performed in mice and rats. All
experiments were approved by the Animal Ethical Committee of
the University of Utrecht and performed in accordance with na-
tional guidelines for the care and handling of animals. C57Bl/6 J
mice (12 weeks old; Harlan, Horst, The Netherlands) received
recombinant human CCN-2 by tail vein injection (25 pmol/g
bodyweight, single dose) (Gerritsen et al. 2010). A blood sample
was drawn by cheek puncture to determine the initial plasma
concentration in each individual mouse. To evaluate the plasma
disappearance and uptake in organs, mice were sacrificed at var-
ious time points (n = 2 per time point). Kidneys, liver, lungs,
heart and spleen were harvested, weighed, and processed for
ELISA or immunohistochemistry, as described below. To evalu-
ate the effects of blocking of LRP1 or HSPGs two separate
groups of mice received either GST-RAP (0.7 nmol/g
bodyweight, n = 8) or protamine hydrochloride (ICN
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Biomedicals, Zoetermeer, The Netherlands) (5 nmol/g
bodyweight, n = 7), respectively, or vehicle (n = 6 for both
experiments) by tail vein injection 1 min before CCN-2 injection
in the other tail vein (25 pmol/g bodyweight). Previous reports
showed that these amounts of RAP and protaminewere adequate
to saturate LRP1 and to block HSPGs sufficiently to influence
the pharmacokinetics of its ligands, respectively (Saenko et al.
1999; Gerritsen et al. 2010; Narita et al. 1995).
Studies in rats were performed to quantify renal and non-
renal CCN-2 clearance.MaleWistar-Kyoto rats (15–17 weeks
old; Harlan) were anaesthetized and instrumented as described
(Gerritsen et al. 2010). After a 45 min stabilization period,
infusion of full length CCN-2 was started at 54 pmol/kg/
min, based on pilot clearance studies. Inulin (Inutest,
Fresenius Pharma, Linz, Austria) and PAH (Sigma, St Louis,
MO) were infused for renal clearance measurements. Urine
was collected at 15 min intervals. 90 Min after the start of
CCN-2 infusion two arterial blood samples were taken at an
interval of 30 min. After a short equilibration period a third
arterial blood sample was taken simultaneously with puncture
of the left renal vein to determine renal extraction and clear-
ance. Inulin and PAH were measured as described (Verseput
et al. 1997).
CCN-2 enzyme-linked immunosorbent assay
Recombinant human CCN-2 levels in plasma, urine, and
tissue homogenates were determined by sandwich
enzyme-linked immunosorbent assay (ELISA), detecting
both full length CCN-2 and the N-terminal fragment. A
human CCN-2 specific assay was used, that does not
cross-react with rodent CCN-2, as described (Gerritsen
et al. 2010; Gerritsen et al. 2015). Frozen renal tissue
(stored at −80 °C) was homogenized in lysis buffer
(20 mM Tris (Roche, Mannheim, Germany), 150 mM
NaCl (Merck, Darmstadt, Germany), 1 % Triton X-100,
10 % glycerol, 1 mM EDTA (Riedel-de Haen, Seelze,
Germany), 0.1 % SDS (Research Organics, Cleveland,
OH), 1 mM EGTA, 0.5 % sodium deoxycholate, 50 mM
NaF, 2 mM Na-orthovanadate (Sigma), pH 7.4) containing
5 % Protease Inhibitor Cocktail (Sigma). Microtiter plates
(Maxisorb; Nunc, Roskilde, Denmark) were coated with
capture anti- CCN-2 monoclonal antibody (5 μg/ml;
FibroGen). Subsequently, diluted samples and standards
(recombinant human CCN-2; FibroGen) were added and
incubated with non-cross-blocking human anti- CCN-2
monoclonal antibody conjugated directly to alkaline phos-
phatase (0.5 μg/ml; FibroGen). Para-nitrophenylphosphate
(Sigma) was used as substrate for the colorimetric reac-
tion. Assay sensitivity (lower limit of detection) was
20 pmol/L. Intra- and interassay coefficients of variation
were below 10 %.
Immunofluorescence
Immunostaining for CCN-2 was performed on 3 μm formalin-
fixed paraffin-embedded tissue sections. After deparaffinization,
antigen retrieval was performed by predigestion with Protease
XXIV (0.2 M phosphate; Sigma) followed by blocking of en-
dogenous peroxidase activity (1 % H2O2 in phosphate/citrate
buffer). Sections were incubated with CCN-2-specific human
monoclonal antibody (FibroGen) (24 μg/ml in PBS/1 % BSA)
for 1 h followed by incubation with rabbit anti-human IgG
(Dako, Glostrup, Denmark) (1:100, 30 min). Amplification was
performed with Powervision poly-peroxidase goat anti-rabbit
IgG (Klinipath, Duiven, The Netherlands) (30 min) and FITC
Tyramide Amplification Reagent (PerkinElmer, Boston, MA)
(1:50, 10 min). TO-PRO 3 Iodide (Molecular Probes, Eugene,
OR) was used for nuclear counterstaining. Slides were mounted
in Vectashield (Vector Laboratories, Ontario, Canada), and visu-
alized by fluorescence and confocal laser scanning microscopy.
For all stainings, incubation with secondary antibody alone
served as a negative control.
Surface Plasmon resonance analysis
Real-time binding experiments were performed on the
Biacore T100 (GE Healthcare, Uppsala, Sweden). LRP1 was
immobilized on a Series S CM5 sensor-chip surface at 3.4
fmol/mm2. One control flow channel was routinely activated
and blocked in the absence of protein. Association of recom-
binant human CCN-2 and its proteolytic fragments and inhi-
bition by RAP were assessed in 10 mM Hepes (pH 7.4),
150 mM NaCl, 5 mM CaCl2 and 0.005 % surfactant P20 for
2 min, at a flow rate of 20 μl/min at 25 °C. Dissociation was
allowed for 2 min in the same buffer flow. Sensor chips were
regenerated using EDTA 125 mM, NaCl 0.5 M during at a
flow rate of 20 μl/min for 30 s. Proteins were injected until
binding equilibrium was reached. Data were corrected for
both refractive index changes and were analyzed with
BIAcore T100 evaluation software (version 2.01). Affinity
constants were determined by steady-state analysis. The inhib-
itory effect of RAP on the interaction of CCN-2 with LRP1
was assessed by adding RAP (3 μM) to immobilized LRP1
followed by CCN-2 (1 μM). Subsequently, binding of CCN-2
to RAP-saturated LRP1 was compared with that of CCN-2
(1 μM) to LRP1 in the absence of RAP.
Calculations and statistics
Data are expressed as mean ± SE and were compared with
Student’s t-test (2-tailed). Pharmacokinetic analysis was per-
formed using a nonlinear two-compartment model (Multifit
program, Department of Pharmacokinetics and Drug
Delivery, University of Groningen, The Netherlands)
(Prakash et al. 2006). Renal clearances of inulin and PAH
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were calculated by standard formulae. Total CCN-2 clearance
was calculated as follows:
infusion rate
arterial concentration
Renal vein concentration was used to determine the amount
of CCN-2 extracted by the kidney and renal CCN-2 clearance
was calculated as follows:
arterial concentration ERPFð Þ− renal vein concentration ERPF−V•
  
arterial concentration
where ERPF is the effective renal plasma flow and V
•
the
urinary flow rate.
Results
Circulating full length CCN-2 is primarily eliminated
by hepatic metabolism
First, we investigated the pharmacokinetic profile of recombi-
nant human CCN-2 that was administered intravenously as a
single bolus to healthy mice. Human CCN-2 specific antibod-
ies were used to distinguish recombinant human CCN-2 from
endogenous CCN-2. The plasma disappearance curve is
shown in Fig. 1a. The initial distribution volume was relatively
large for a hydrophilic protein such as CCN-2: 454 ± 47 mL/
kg. This value exceeds plasma and extracellular fluid volume
suggesting tissue binding of CCN-2. The plasma disappear-
ance rate during the first 15 min was fast with an initial clear-
ance of 120 ± 11 mL/kg/min corresponding to an initial half-
life of 2.6 ± 0.02 min. Since plasma levels dropped rapidly to
very low levels, no reliable pharmacokinetic data could be
obtained after the initial distribution phase. To obtain a more
accurate estimate of CCN-2 clearance and to quantify renal and
non-renal clearance, additional experiments were conducted
with continuous CCN-2 infusion. Because we had to take mul-
tiple blood samples, we performed these experiments in anaes-
thetized rats. After reaching steady state, kinetic parameters
were calculated from plasma concentrations and urinary excre-
tion, as summarized in Table 1. Total CCN-2 clearance was
derived from steady state plasma concentration and infusion
rate. For determination of renal extraction and clearance, blood
samples were drawn simultaneously from the renal vein and
femoral artery. Total CCN-2 clearance was 45 ± 8 mL/kg/min
with renal clearance 5.4 ± 0.8 mL/kg/min, accounting for only
~12 % of total clearance, indicating that the majority of the
protein was cleared via a non-renal route.
To investigate CCN-2 tissue distribution we measured
CCN-2 tissue levels and performed immunohistochemistry
after single bolus injection in mice. We observed rapid accu-
mulation of CCN-2 in the liver and to a lesser extent in the
kidney (Fig. 1b-d). Immunofluorescent staining showed up-
take of CCN-2 in intracellular organelles in hepatocytes
(Fig. 1e), which was observed only temporarily during the
first 15 min after injection suggestive of rapid hepatic metab-
olism. In the kidney, CCN-2 was filtered and subsequently
endocytosed to a large extent by proximal tubular cells, as
reported previously (Gerritsen et al. 2010). We found practi-
cally no distribution to other tissues including lung, heart or
spleen. Thus, in healthy rodents circulating full length CCN-2
is primarily eliminated by the liver and to a lesser extent by the
kidney.
RAP prolongs CCN-2 half-life and prevents CCN-2
internalization by hepatocytes
We studied the effect of RAP, an antagonist of low density
lipoprotein receptor (LDLR) family proteins, on the pharma-
cokinetic profile of CCN-2. In mice, intravenous injection of
an excess of GST-RAP 1 min prior to intravenous bolus in-
jection of CCN-2 reduced elimination rate of CCN-2 after a
comparable initial distribution phase (Fig. 2a), resulting in
5-fold higher plasma CCN-2 concentrations at 10–15 min
after injection (p < 0.001). Immunohistochemistry showed
less uptake in intracellular organelles in hepatocytes, suggest-
ing reduced intrahepatic degradation (Fig. 2b). These results
suggest that hepatic metabolism of circulating CCN-2 is de-
pendent on its uptake in hepatocytes by an LDLR family
member, most likely LRP1. RAP has high affinity for LRP1
(Kd 5.4 nM) and is known to inhibit binding and endocytosis
of all known LRP1 ligands (Williams et al. 1992).
Administration of a bolus GST-RAP alone did not result in
detectable levels of circulating endogenous full length CCN-2
15 min after injection (data not shown). This indicates that
CCN-2 release from tissues is very low in healthy mice.
To confirm that CCN-2 is an LRP1 ligand, we performed
surface plasmon resonance analysis with immobilized LRP1.
CCN-2 bound to LRP1 in a dose-dependent manner (Fig. 2c).
The binding affinity (Kd) of this interaction was calculated to
be 116 ± 22 nM. Interaction of CCN-2 with LRP1 was at least
partially inhibited by RAP (Fig. 2d). Next, interaction of in-
dividual proteolytic CCN-2 fragments with LRP1 was ana-
lyzed. Interestingly, the C-terminal part of CCN-2 interacted
with LRP1 (Kd = 112 ± 7 nM) with similar affinity as did full-
length CCN-2. In contrast the N-terminal part of CCN-2 did
not show any binding to immobilized LRP1, up to concentra-
tions of 1 uM. These data indicate that LRP1 binds to CCN-2
through LRP binding sites in its C-terminal moiety.
Blocking of HSPGs reduces CCN-2 distribution volume
in vivo
To examine how binding of HSPGs in vivo influenced the
pharmacokinetic profile of plasma CCN-2, we performed
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clearance studies in the presence of an excess of protamine,
which prevents HSPGs from interacting with their ligands
(Warshawsky et al. 1996; Narita et al. 1995). Protamine
administered as a single dose 1 min prior to CCN-2 injec-
tion resulted in about 7-fold higher plasma CCN-2 levels at
all time points as compared to single CCN-2 bolus injec-
tion (p < 0.05, Fig. 3a) and in a decrease of interstitial
staining 5 min after bolus injection, in particular in the
kidney (Fig. 3b). The parallel shift of the plasma disappear-
ance curve indicates that the distribution volume of CCN-2
was reduced, while clearance remained unaffected by prot-
amine. Thus, binding to HSPGs appears to be involved in
distribution of full length CCN-2 but not in its elimination
from the circulation.
Fig. 1 Pharmacokinetic profile
after single intravenous dose of
recombinant human CCN-2 in
mice. a Plasma disappearance
curve of CCN-2. Plasma
concentration expressed as
percentage of injected dose per mL
plasma. Each dot represents one
animal. b-c Immunofluorescence
of liver b and kidney c, 15 min
after CCN-2 administration, by
using human anti- CCN-2 (green),
visualized by fluorescence
microscopy. d Estimated organ
levels expressed as percentage of
injected dose of recombinant
human CCN-2 5–10 min
after intravenous CCN-2
administration in mice (n = 8).
e Immunofluorescence of liver by
using human anti- CCN-2 (green)
and TO-PRO 3 Iodide for nuclear
staining (red), visualized by
confocal laser scanning
microscopy
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Table 1 Clearance of recombinant human full length CCN-2 in
healthy rats
Parameter N = 4
Body weight (g) 309 ± 11
Mean arterial pressure (mmHg) 101 ± 2
GFR (mL/kg/min; inulin) 9.0 ± 0.1
Renal plasma flow (mL/kg/min; PAH) 30 ± 1
Total CCN-2 clearance (mL/kg/min) 45 ± 8
Renal CCN-2 clearance (mL/kg/min) 5.4 ± 0.8
Values are means ± SE. GFR, glomerular filtration rate; PAH, para-
aminohippuric acid
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Discussion
The main finding of our studies is that circulating full length
CCN-2 is primarily cleared by fast hepatic metabolism via a
RAP-sensitive pathway, most likely involving LRP1.
Full length CCN-2 distributed mainly to the liver and was
taken up by hepatocytes. The half-life of CCN-2 was markedly
prolonged and hepatic uptake substantially reduced after ad-
ministration of RAP, which suggests that uptake in hepatocytes
is mediated by an LDLR family protein. This is in accordance
with previous in vitro cell binding experiments, showing that
CCN-2 is an LRP1 ligand (Segarini et al. 2001; Gao and
Brigstock 2003). We confirmed this by surface plasmon reso-
nance analysis. Rapid disappearance of all intracellular inclu-
sions in hepatocytes 30 min after bolus injection in mice sug-
gests fast degradation after endocytosis, in line with rapid
LRP1-mediated internalization and subsequent intracellular
degradation as observed in vitro (Segarini et al. 2001). LRP1
is responsible for plasma clearance of various proteins includ-
ing coagulation factors and lipoprotein remnants (Lillis et al.
2008). LRP1 is most prominent in liver, but is also present in
various other tissues, including lung, central nervous system
and lymphoid tissues (Moestrup et al. 1992). Interestingly, mice
in which the LRP1 gene is deleted in smooth muscle cells
developed aortic dilatation andmedial thickening that is accom-
panied by local accumulation of the CCN-2 protein, indicating
that LRP1 maintains the vasculature integrity by modulation of
CCN-2 protein levels (Muratoglu et al. 2013). We did not ob-
serve evident CCN-2 accumulation in vessels, lung, heart or
spleen. Inhibition of LRP1 binding by RAP has been applied
before to prove LRP1-involvement in clearance of various
LRP1 ligands in vivo (Narita et al. 1995; Saenko et al. 1999;
Sarafanov et al. 2001; Schwarz et al. 2000). In addition to
LRP1, RAP is known to block ligand binding to other
endocytic cell surface receptors of the LDL receptor family
members (Bovenschen et al. 2003).
Previous reports found that CCN-2 binds LRP1 via domain
3, since blocking of LRP1 reduced binding of full length
CCN-2 and the C-terminal half, but not binding of domain 4
alone, to activated hepatic stellate cells (Gao and Brigstock
2003). Surface plasmon resonance experiments now confirm
that CCN-2 is indeed binding via an epitope on its C-terminal
half to LRP1, in agreement with previous pharmacokinetic
studies with the N-terminal fragment of CCN-2, that did not
show any hepatic uptake in vivo (Gerritsen et al. 2010).
Thus far, elevated plasma levels of full length CCN-2 in
chronic liver disease have been considered to be secondary to
increased production in fibrotic liver tissue (Gressner et al. 2006;
Guo-Qiu et al. 2010). Increased platelet activation in advanced
liver disease (Panasiuk et al. 2001) might also contribute to ele-
vated CCN-2, since platelets contain large amounts of full length
CCN-2 that is released upon activation (Cicha et al. 2004;
Miyazaki et al. 2010). We here show that hepatic metabolism
Fig. 2 a-b Pharmacokinetic profile after single intravenous dose of
recombinant human CCN-2 preceded by injection of an excess of GST-
RAP in mice. a Plasma disappearance curve of CCN-2. GST-RAP prior
to CCN-2 reduced the elimination rate but not initial distribution. Plasma
concentration is expressed as percentage of injected dose per mL plasma.
Each dot represents one animal. b Immunofluorescence of liver 15 min
after CCN-2 administration, by using human anti- CCN-2 (green),
visualized by confocal laser scanning microscopy. GST-RAP prior to
CCN-2 (right) reduces uptake in hepatocytes. c-e Surface plasmon
resonance analysis of human CCN-2 and its proteolytic fragments, run
over immobilized LRP1. Response is depicted as pg/mm2. c Dose-
dependent response with concentrations of full length CCN-2 of 0,
6.25, 12.5, 25, 50, 100 and 200 nM. d Interaction of CCN-2 (1 uM) (I)
with LRP1 is partially inhibited by GST-RAP (3 uM) (II). e Full length
CCN-2 (200 nM) (I) and C-terminal fragment (200 nM) (II), but not N-
terminal fragment (200 nM) (III), show interaction with LRP1
Fig. 3 a-b Pharmacokinetic profile after single intravenous dose of
recombinant human CCN-2 preceded by injection of an excess of protamine
in mice. a Plasma disappearance curve of CCN-2. Administration of
protamine prior to CCN-2 reduced distribution volume but not elimination
rate. Plasma concentration is expressed as percentage of injected dose per mL
plasma. Each dot represents one animal.b Immunofluorescence of kidney and
liver, 5min after CCN-2 administration, by using human anti- CCN-2 (green),
visualized by confocal laser scanning microscopy. Protamine prior to CCN-2
(right) reduces interstitial staining
R
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is the main elimination route of full length CCN-2. Hence re-
duced elimination might also contribute to accumulation of full
length CCN-2 in advanced liver disease (Kovalenko et al. 2009;
Zhang et al. 2009; Guo-Qiu et al. 2010). Hollestelle et al. showed
that liver cirrhosis is associated with decreased expression of
LRP1 (Hollestelle et al. 2004). However, additional experiments,
e.g. elimination studies in experimental liver cirrhosis, would be
needed to explore the postulated contribution of reduced hepatic
removal to elevated CCN-2 levels in chronic liver disease.
In mice we found a relatively large initial distribution vol-
ume exceeding the extracellular fluid volume which is re-
markable for a hydrophilic glycosylated protein of approxi-
mately 37 kD and suggests tissue or plasma protein binding.
Previous studies reported in vitro binding of CCN-2 to HSPGs
(Gao and Brigstock 2004), which are widely distributed in all
tissues. The substantial decrease in distribution volume of
CCN-2 after administration of protamine suggests that CCN-
2 also binds to HSPGs in vivo. This is supported by the find-
ing that interstitial staining in the kidney was markedly re-
duced after protamine administration, although in the liver this
was less evident, possibly as a consequence of CCN-2 binding
to other molecules, including LRP1. In vitro, CCN-2 binds to
HSPGs via domain 4 on its C-terminal half (Gao and
Brigstock 2004). Consistently, interstitial staining in the kid-
ney was virtually absent after in vivo administration of the N-
terminal fragment (Gerritsen et al. 2010). Binding to HSPGs
has been shown to facilitate LRP1 mediated degradation of
the LRP1 ligands factor VIII and tissue activator pathway
inhibitor (Sarafanov et al. 2001; Narita et al. 1995; Lillis
et al. 2008). However, for CCN-2 we observed no increase
of plasma half-life upon blocking its binding to HSPGs by
protamine, suggesting that in vivo CCN-2 degradation by
LRP1 is not facilitated by binding to HSPGs.
We used antibodies detecting both full length CCN-2 and the
N-terminal fragment for immunohistochemistry and ELISA.
Although experiments were of short duration, proteolytic cleav-
age of the full length molecule into its N- and C-terminal halves
could theoretically have influenced the results. This seems un-
likely, since in similar experiments with the N-fragment, we ob-
served a much smaller distribution volume, efficient renal clear-
ance and no hepatic uptake at all (Gerritsen et al. 2012).
Although we cannot exclude that the small percentage of renal
clearance observed upon infusion studies of full length CCN-2 in
rats was partly due to N-fragment clearance, some glomerular
sieving is also not unlikely for the full length protein that has a
diameter of 36–38 kDa.
In conclusion, our findings show that full length CCN-2 is
primarily eliminated by the liver via a fast RAP-sensitive,
probably LRP1-mediated, pathway. The large initial distribu-
tion volume of full length CCN-2 is due to a protamine-
sensitive process, presumably CCN-2 binding to HSPGs, but
we have no indication that CCN-2 interaction with HSPGs
facilitates RAP-sensitive hepatic catabolism.
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